Mounjaro®
Starting from £179.99/mo
Start journey Learn moreThe honest answer: yes, 5mg tirzepatide is a therapeutically active dose in a way that 2.5mg simply is not. The 2.5mg pen exists to let your body adjust, not to drive meaningful weight loss. Most people notice a real shift in appetite when they move to 5mg. That said, these are prescription-only medicines and a GPhC-registered prescriber decides whether and when a dose increase is right for you, based on how your body has responded and your full medical picture. If you've just moved up and you're wondering whether the change will be worth it, read on — the evidence is fairly clear.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Here's the situation many people find themselves in: four weeks in, the nausea settled after week two, but the scales haven't moved much. That's expected. The 2.5mg dose of Mounjaro (tirzepatide) is a tolerability step, its job is to train your digestive system to accept the medicine, not to suppress appetite significantly. Eli Lilly designed it that way deliberately, and the NHS tirzepatide patient information reflects this: 2.5mg is the starting dose, typically for four weeks only, before moving up.
At 5mg, tirzepatide begins acting as a dual GIP and GLP-1 receptor agonist at a clinically meaningful level. Both receptor pathways work together to slow gastric emptying and reduce appetite. People often describe week one at 5mg as noticeably different, food just feels less compelling. That's the mechanism starting to work. It's not placebo; it's pharmacology.
One practical note: your first 5mg pen arrives by DPD the next working day, tracked to your door, in a plain cardboard box with no branding. Inside is a single KwikPen containing four weekly doses. The change from 2.5mg to 5mg is the same pen format, just a different colour band.
The SURMOUNT-1 trial, published in the New England Journal of Medicine, tested tirzepatide across multiple doses in adults with obesity over 72 weeks. The 5mg dose produced around 15% average body-weight reduction by week 72. The 2.5mg dose was a tolerability phase, not a maintenance dose, so it was not tested as a standalone treatment in that trial. At 10mg the average was around 19.5%, and at 15mg around 20.9%, which represents the upper end of what tirzepatide can offer. The direction is clear: higher doses produce greater average weight loss, up to the ceiling of what the treatment can offer.
The table below sets this out factually.
| Dose | Role in treatment | Average weight loss at 72 weeks (SURMOUNT-1) |
|---|---|---|
| 2.5mg | Tolerability/starter only, not a maintenance dose | Not assessed as standalone maintenance |
| 5mg | First active maintenance dose | ~15% average body-weight reduction |
| 10mg | Mid-range maintenance | ~19.5% average |
| 15mg | Maximum licensed dose | ~20.9% average |
These are group averages from a clinical trial population. Individual responses vary. A prescriber considers your personal response at each dose before recommending any increase, which is why the titration schedule exists and why going higher isn't automatically better for every person.
Most people find that side effects peak when they first start or after each dose step, then ease within one to two weeks. Moving from 2.5mg to 5mg can briefly reintroduce nausea, looser stools or fatigue, the same GI-led profile that appeared at the start, usually milder the second time around because the body has already adapted to the medicine. Common effects at both doses include nausea, indigestion, constipation and occasional burping. At 5mg, these effects are generally more noticeable than at 2.5mg, but they tend to be short-lived.
On any dose, the MHRA asks patients to report suspected side effects via the Yellow Card scheme. If you experience severe, persistent stomach pain that radiates to your back, seek medical attention promptly rather than waiting for your next check-in. That symptom warrants urgent assessment. For everything else (queasiness, mild digestive changes) your prescriber and the Patient Information Leaflet are the right starting points. There's more on managing the adjustment period in our full Mounjaro guide.
A dose increase from 2.5mg to 5mg isn't automatic. At nume, a GPhC-registered prescriber reviews your consultation and, for repeat orders, your reported response before approving the next pen. If 2.5mg hasn't settled well (significant ongoing nausea, vomiting that interferes with daily life) staying at 2.5mg a little longer or addressing tolerability first may be the right call. If you've tolerated it well, 5mg is the expected next step.
The question of whether 5mg works better than 2.5mg has a factual answer: yes, for weight reduction, it does. Whether the move is right for you right now is a clinical question. Our prescribers work through that with you at every stage, it's what the same-day review process is built for. You can find broader context on what to expect from the 5mg dose, and if you're thinking about the full titration picture, how the 2.5mg phase fits in may help too.
For anyone considering starting treatment, the free consultation is the right first step. Eligibility depends on your BMI, medical history and a prescriber's assessment, not just the numbers on this page.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.